|
 |
Teveten HCTThis page contains recent news articles, when available, and an overview of Teveten HCT but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Teveten HCT is a combination medication used in the treatment of high blood pressure. One component, eprosartan, belongs to a class of blood pressure ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com Biovail sells off its US holdingsBiovail selling US operations; Buyer... - May 4, 2005 ...effort to restructure how it delivers products to general practitioners in the United States, means Biovail will hand over Teveten and Teveten HCT. ... Pay-Per-View - Toronto Star - ProQuest Archiver Q1 2005 Kos Pharmaceuticals Earnings Conference Call - Final. - May 3, 2005 The next slide, #7, provides some background on Teveten and Teveten HCT. ... Teveten and Teveten HCT had total sales of approximately $18 million in 2004 ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Kos Reports 49% Increase in Revenue to $179.4 Million, Earnings Per … - Aug 4, 2005 Kos recorded second quarter 2005 revenue for Teveten/ Teveten HCT of $4.8 million ... Teveten and Teveten HCT, products that possess an impressive clinical ... $4.95 - Business Wire - ECNext Biovail Reports Fourth Quarter, Year-End 2004 Financial Results. - Mar 10, 2005 Biovail's Teveten franchise (Teveten, Teveten HCT) generated revenues of $5.2 million in the fourth quarter of 2004, compared with $2.1 million in the prior ... $4.95 - Business Wire - ECNext Abbott Laboratories: Kos Pharmaceuticals a wise buy - Nov 8, 2006 Furthermore, with Kos having recently licensed a range of hypertensive treatments from the Biovail Corporation, namely Cardizem LA, Teveten and Teveten HCT ... Pharmaceutical Business Review Minnesota - Official Notices - Department of Human Services - Jan 3, 2006 Teveten HCT ACE inhibitors Accupril Capoten Lotensin Mavik Monopril Prinivil Univasc Vasotec Zestril ACE inhibitorsdiuretic combinations Accuretic Prinizide ... Pay-Per-View - RegAlert - Factiva, from Dow Jones Kos Reports Continued Double Digit Increase in Revenue, Financial … - Sep 5, 2006 Revenues for Kos' hypertension portfolio, comprised of Teveten(R),Teveten HCT and Cardizem(R)LA, totaled $31.6 million, excluding a $1.6million reduction in ... FINANZEN.NET NEWS - FINANZEN.NET NEWS Kos to Report Third Quarter Results on November 9, 2006 Conference … - Nov 9, 2006 CRANBURY, NJ--(BUSINESS WIRE)--Kos Pharmaceuticals, Inc. (Nasdaq:KOSP), a fully integrated specialty pharmaceutical company, will announce results for the ... businesswire.com Biovail Corporation Commences Offer to Purchase $56.6 Million of Its ... - May 25, 2006 ...resulting from the sale of Biovail's product rights and certain inventories related to Teveten and Teveten HCT to Kos Pharmaceuticals, Inc. in May 2005. ... Free with registration - Business Wire - AccessMyLibrary.com Kos Pharmaceuticals Inc acquires BioVail Corp-Teveten Rights from … - May 3, 2005 The agreement resulted in the…in the disposal of all rights to the company's Teveten and Teveten HCT hypertensive product portfolio. In… ... Pay-Per-View - deals - Alacra Store Q2 2005 Kos Pharmaceuticals Earnings Conference Call - Final. - Aug 4, 2005 And secondly, the successful integration of the newly acquired cardiovascular products, Cardizem LA, Teveten, and Teveten HCT, which we purchased from ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Biovail Reports Second-Quarter 2006 Financial Results; Company … - Aug 10, 2006 ...a write-down of assets primarily associated with the sale of Teveten and Teveten HCT to Kos Pharmaceuticals, Inc., and a $4.9-million write-off of ... $4.95 - Business Wire - ECNext UP-OR-OUT RULES CAN CREATE HARDSHIPS ALL AROUND - May 8, 2005 Nexium and two other drugs --- Teveten and Teveten HCT, for high blood pressure --- are the first to be moved to non-formulary status, a new third tier of ... $2.95 - Macon Telegraph - NewsBank Merger and Acquisition Scenario - Mar 11, 2006 Teveten HCT (Eprosartan/Hydrochlorothiazide). Calcium Channel Blocking Agents. Therapeutics that treat high blood pressure by blocking the beta adrenergic ... $250.00 - Revere Reports - Revere Company Profile Report - Dec 16, 2006 Teveten HCT (Eprosartan/Hydrochlorothiazide). Calcium Channel Blocking Agents. Products:. Cardizem LA (Diltiazem Hydrochloride). Peripheral Vascular Disease ... $50.00 - Revere Reports - Revere Biovail Reports Second-Quarter 2005 Financial Results. - Aug 4, 2005 As part of the agreement with Kos, Biovail divested the Teveten and Teveten HCT products, and entered into a supply agreement for Cardizem(R) LA in the US ... $4.95 - Business Wire - ECNext Finance; Biovail reports revenues of $253 million - Sep 12, 2006 ...a write-down of assets primarily associated with the sale of Teveten and Teveten HCT to Kos Pharmaceuticals, Inc., and a $4.9-million write-off of ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Drug/Medical Device - Dec 16, 2006 Teveten HCT (Eprosartan/Hydrochlorothiazide), Hypertension, Upper Respiratory Tract Infections, Rhinitis, Pharyngitis, Cough, Fatigue, Viral Infections, ... $70.00 - Revere Reports - Revere COMUNICADO: Abbott ampliará su presencia en el mercado de … - Nov 6, 2006 La compañía comercializa actualmente Niaspan, Advicor, Azmacort, Cardizem LA, Teveten y Teveten HCT. Kos tiene una línea de proyecto sólida y cada vez mayor ... elEconomista.es |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |